Mechanisms of Action of GLP-1 Agonists in T2D

April 29, 2019 12:36 pm

Expert colleagues react to the benefits demonstrated through data with the use of GLP-1 agonists for the treatment of type 2 diabetes and explore how the various options work.

Category: News
About The Author
-
Previous

GLP-1 Agonist Therapy in a Patient With T2D and CVD
Next

Type 2 Diabetes and Cardiovascular Disease: Risk Factors

Related Videos

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

Diabetes-Epigenome-Atlas-DGA-and-T2D-Knowledge-Portal-September-26-2019-Webinar

Diabetes Epigenome Atlas (DGA) and T2D Knowledge Portal: September 26, 2019 Webinar

Introduction-to-SGLT2-Inhibition

Introduction to SGLT2 Inhibition

Type-2-Diabetes-Dr-Stephen-Hull-Practical-Advice-for-People-with-T2D-and-Heart-Disease

Type 2 Diabetes: Dr Stephen Hull – Practical Advice for People with T2D and Heart Disease

Diabetologists-Perspective-of-Diabetes-and-Cardiovascular-Risk-Management-in-Post-ACS-T2D-patients

Diabetologist’s Perspective of Diabetes and Cardiovascular Risk Management in Post-ACS T2D patients

Rogelio-Braceras-MD-Improving-Costs-Comorbidities-in-T2D

Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D